Exelixis Reiterates CABO Growth Strategy, Zanzalintinib Catalysts Ahead

What happened

Exelixis’s SVP of strategy reiterated plans to expand the Cabometyx franchise while awaiting key zanzalintinib data and a potential CRC approval, according to an RBC Capital Markets-hosted session. The company remains heavily dependent on Cabometyx, which generates over 80% of revenue and faces patent-cliff risk starting 2026, with the stock already pricing in much of the near-term upside. Zanzalintinib’s late-2026+ revenue optionality is not yet de-risked, and any delays or weak launch could leave Exelixis without a second growth engine before generic pressure intensifies. While the narrative continues to emphasize momentum and pipeline progress, the DeepValue report flags a well-owned stock with a limited margin of safety and advises waiting for a pullback or clearer evidence of above-guidance execution. This conference appearance does not alter the fundamental risk-reward calculus, which remains skewed toward patience given the single-product concentration and 2026–2033 patent corridor.

Implication

Exelixis offers a strong Cabometyx cash-flow engine but trades at ~17x EPS with limited margin of safety, as zanzalintinib’s CRC approval and patent-cliff risks loom. The stock has run ~28% over 12 months, and institutional selling signs (IBD D rating) suggest some profit-taking. Near-term catalysts like STELLAR-304 data and FDA acceptance of the CRC NDA could drive upside, but any misstep on zanzalintinib or Cabometyx share loss would likely lead to material downside. Position sizing should assume higher risk, and investors should consider trimming above $52 or adding on dips below $38. The base-case upside to $48 is not compelling given 20–25% downside if growth falters, so a WAIT rating remains appropriate until more de-risking occurs.

Thesis delta

Thesis unchanged; the news reinforces existing expectations for CABO growth and zanzalintinib milestones, but does not improve risk-reward. The DeepValue report’s WAIT rating stands, with no new data to alter the assessment of limited margin of safety and crowded positioning.